(Q34268879)

1 August 2017

1 reference

title

Recent advances in the clinical application of aromatase inhibitors (English)

1 reference

1 August 2017

Harper-Wynne C

1

1 reference

1 August 2017

Dowsett M

series ordinal

2

1 reference

1 August 2017

publication date

1 January 2001

1 reference

The Journal of Steroid Biochemistry and Molecular Biology

1 August 2017

published in

1 reference

1 August 2017

volume

76

1 reference

1 August 2017

issue

1-5

1 reference

1 August 2017

page(s)

179-186

1 reference

Recent advances in endocrine therapy of breast cancer

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Low-dose aminoglutethimide in treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Compensatory Increase in TSH Secretion without Effect on Prolactin Secretion in Patients Treated with Aminoglutethimide

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Aromatase and its inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SA

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Inhibition of aromatase in vitro and in vivo by aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

The primary use of endocrine therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Lessons from the use of aromatase inhibitors in the neoadjuvant setting

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Aromatase inhibitors and their future role in post-menopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Evidence that Tamoxifen Preserves Bone Density in Late Postmenopausal Women with Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

The potential of aromatase inhibitors in breast cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Risks versus benefits in the clinical application of aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Aromatase and gynecomastia

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Use of aromatase inhibitors in precocious puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

Treatment of severe postmenopausal endometriosis with an aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2800%2900150-3

7 January 2021

10.1016/S0960-0760(00)00150-3

Identifiers

DOI

1 reference

1 August 2017

1 reference